Drugs can wear costumes, too. This year, the darling of the pharmaceutical sector, the glucagon-like peptide 1 (GLP-1) agonist drug class, dressed up as a boogeyman, and set its sights on the medtech sector.
No, I Am Spartacus – Embecta Joins The Quell Against GLP-1 Hype
Embecta, which recently completed its spin-off from Becton Dickinson, is forging ahead with its insulin injector-based business strategy, GLP-1s be damned.
